Adults living with IgA nephropathy, the most common form of kidney inflammation worldwide, now have access to a drug designed not just to reduce protein in urine but to slow the loss of kidney function itself. The FDA granted accelerated approval to iptacopan, sold as Fabhalta, for adults with primary IgA nephropathy at risk of rapid disease progression. The decision rested on data from the phase 3 APPLAUSE-IgAN trial, which tracked patients over 24 months and showed both a sustained drop in proteinuria and a slower decline in the filtration rate that measures how well kidneys work.
Why iptacopan’s accelerated approval changes the treatment calculus for IgA nephropathy
IgA nephropathy damages kidneys gradually, often over decades, and a significant share of patients eventually require dialysis or transplant. Until recently, no FDA-approved therapy was built specifically to address the disease’s underlying complement-pathway mechanism. The agency’s earlier approval of Tarpeyo marked the first attempt to lower proteinuria in IgA nephropathy, but that drug targeted a different biological pathway and relied on the same surrogate endpoint: proteinuria reduction. Iptacopan works by blocking the alternative complement pathway, a part of the immune system that, in IgA nephropathy patients, drives inflammation and scarring inside the kidney.
The distinction matters for patients and nephrologists weighing treatment options. Proteinuria reduction is a useful marker, but the real clinical question is whether lower protein levels translate into preserved kidney function over years. The APPLAUSE-IgAN trial, registered as NCT04578834, was designed to answer both questions. Its interim analysis showed a significant proteinuria reduction at nine months, which the FDA accepted as the basis for accelerated approval. The final 24-month dataset, published in the New England Journal of Medicine, extended those findings by reporting kidney-function slope data alongside sustained proteinuria results.
A reasonable hypothesis, testable as more data emerge, is that iptacopan’s proteinuria reduction will translate into a measurable delay in dialysis initiation primarily among patients who still had relatively preserved kidney function at the start of treatment. That pattern would mirror what clinicians see with other kidney therapies: earlier intervention yields larger long-term gains. The ongoing post-marketing requirement study, listed on the FDA’s accelerated-approval ledger as a formal confirmatory obligation, should eventually provide the stratified estimated glomerular filtration rate (eGFR) data needed to test that idea.
APPLAUSE-IgAN trial data and what the FDA weighed
The final 24‑month results from APPLAUSE-IgAN represent the most complete efficacy picture available for iptacopan in this disease. The trial enrolled adults with primary IgA nephropathy and measured two co-primary endpoints: the change in proteinuria and the rate of eGFR decline over time. By publishing both interim and final data in the same peer-reviewed journal, the investigators created a transparent evidence chain linking the surrogate endpoint that earned accelerated approval to the longer-term kidney-function outcome the FDA wants confirmed.
The FDA itself distinguishes several expedited pathways, and the terminology matters. Fast Track designation, Breakthrough Therapy designation, Accelerated Approval, and Priority Review each carry different evidentiary standards and review timelines, according to the agency’s own explanatory guidance. Iptacopan’s path through accelerated approval means the FDA concluded that proteinuria reduction was reasonably likely to predict clinical benefit but has not yet confirmed that benefit with a completed confirmatory trial. The agency’s accelerated-approval ledger lists the required post-marketing study, tying Fabhalta’s continued market access to verification of eGFR outcomes.
Iptacopan is not the only IgA nephropathy drug to receive expedited treatment. The FDA also approved Voyxact, a monoclonal antibody called sibeprenlimab-szsi, for primary IgA nephropathy under expedited review pathways. That approval further signals the agency’s willingness to use surrogate endpoints and faster review timelines for a disease that previously had almost no targeted therapies. Each of these drugs attacks a different part of the immune cascade, giving nephrologists distinct mechanistic options but also raising questions about which patients benefit most from which approach.
Gaps in the evidence and what patients should watch for next
Three significant unknowns hang over iptacopan’s approval. First, the confirmatory post-marketing study has not yet reported final results. Until that study delivers stratified eGFR data, clinicians cannot say with certainty that the proteinuria reductions seen in APPLAUSE-IgAN will prevent or meaningfully delay kidney failure. The FDA can withdraw accelerated approval if confirmatory evidence fails to demonstrate clinical benefit, a safeguard that has been used in other therapeutic areas when surrogate endpoints did not ultimately translate into better outcomes.
Second, long-term safety remains incompletely characterized. By blocking the alternative complement pathway, iptacopan may alter host defenses against certain infections. In the trial, serious adverse events were relatively infrequent, but two years of follow-up cannot fully capture rare complications or risks that accumulate over longer exposure. Patients and clinicians will need clear, updated safety communications as more real-world data accumulate, particularly for those taking iptacopan alongside other immunomodulating therapies.
Third, the optimal place for iptacopan in the treatment sequence is still being defined. Standard care for IgA nephropathy has long centered on blood-pressure control with renin–angiotensin system blockers, plus SGLT2 inhibitors for many patients, and in some cases systemic steroids. With Tarpeyo, Voyxact, and now Fabhalta in the mix, nephrologists face a crowded and expensive landscape. Head-to-head trials are unlikely in the near term, so treatment decisions will hinge on indirect comparisons, patient characteristics, tolerability, and insurance coverage.
For patients, the practical questions are straightforward even if the evidence is not. Who is most likely to benefit from iptacopan-those early in their disease course, or those already experiencing rapid decline? How long should therapy continue once proteinuria falls-indefinitely, or until some stability threshold is reached? And how should clinicians monitor for both efficacy and safety in everyday practice? The confirmatory eGFR data, along with post-marketing safety surveillance, will be central to answering these questions over the next several years.
In the meantime, experts emphasize that iptacopan is an addition to, not a replacement for, foundational kidney-protective strategies. Tight blood-pressure control, careful use of renin–angiotensin system blockade, SGLT2 inhibition where appropriate, and lifestyle measures such as sodium restriction and smoking cessation remain cornerstones of care. For many patients, the most realistic near-term benefit of Fabhalta may be incremental: a slower eGFR decline layered on top of existing therapies, potentially translating into extra years before dialysis or transplant is needed.
The accelerated approval of iptacopan therefore marks both a milestone and a starting point. It validates complement inhibition as a viable strategy in IgA nephropathy and signals the FDA’s willingness to move quickly when a serious disease lacks targeted options and a reasonably predictive surrogate endpoint is available. At the same time, it places a clear evidentiary burden on the sponsor to confirm that short-term biomarker gains yield long-term clinical protection. For patients and clinicians navigating IgA nephropathy, the coming wave of confirmatory data will determine whether Fabhalta ultimately reshapes the disease’s trajectory or remains one more incremental tool in a still-evolving therapeutic arsenal.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
